 VICTORIA, British Columbia--BUSINESS WIRE--- IPA POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. the Company or IPA NASDAQ: IPA TSX VENTURE: IPA a leader in full-service, therapeutic antibody discovery and development, today announced that its subsidiary Talem Therapeutics LLC Talem has advanced development of a candidate panel of vetted, novel, therapeutic antibodies, collectively referred to as TATX-112, against an undisclosed target, into formal lead candidate characterization. It is well documented 